Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era.

Greece Healthcare-associated infections Multidrug resistance Surveillance

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
26 Mar 2024
Historique:
received: 30 11 2023
accepted: 08 03 2024
medline: 26 3 2024
pubmed: 26 3 2024
entrez: 26 3 2024
Statut: aheadofprint

Résumé

From 2019 (pre-COVID-19) to 2022 (COVID-19 years), three tertiary Greek hospitals monitored MDRO bloodstream infection (BSI) and hospital acquisition relying on laboratory data. Surveillance covered carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA), in intensive care units (ICUs) and non-ICUs. Non-ICUs experienced significant increases in CRE, CRAB and VRE during the pandemic. In ICUs, CRE increased in 2021, CRAB in 2020 and 2021, and VRE in 2021 and 2022. KPC predominated among CRE. MDRO BSI and hospital acquisition incidence rates increased, driven by CRE and CRAB.

Identifiants

DOI: 10.1007/s10096-024-04806-x PMID: 38530465
pubmed: 38530465
doi: 10.1007/s10096-024-04806-x
pii: 10.1007/s10096-024-04806-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S. Department of Health and Human Services [Internet] (2022) 14;399:629–55. https://doi.org/10.15620/cdc:117915
Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A et al Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022 12;399:629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Executive Summary Policy Pathways to Combat the Global Crisis of Antimicrobial Resistance www.asm.org/advocacy 1 [Internet]. doi: www.asm.org/advocacy
EClinicalMedicine Antimicrobial resistance: a top ten global public health threat. EClinicalMedicine 2021 1;41. https://doi.org/10.1016/j.eclinm.2021.101221
Monnet DL, Harbarth S Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Euro 2020 1;25:1–6. https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001886
Kritsotakis EI, Kontopidou F, Astrinaki E, Roumbelaki M, Ioannidou E, Gikas A Prevalence, incidence burden, and clinical impact of healthcare-associated infections and antimicrobial resistance: a national prevalent cohort study in acute care hospitals in Greece. Infect Drug Resist 2017 10;10:317–328. https://doi.org/10.2147/IDR.S147459
Ioannou P, Astrinaki E, Vitsaxaki E, Bolikas E, Christofaki D, Salvaraki A et al A Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in Public Acute Care Hospitals in Crete, Greece. Antibiotics 2022 1;11. https://doi.org/10.3390/antibiotics11091258
Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS et al Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019 1;19:56–66. https://doi.org/10.1016/S1473-3099(18)30605-4
Polemis M, Mandilara G, Pappa O, Argyropoulou A, Perivolioti E, Koudoumnakis N et al COVID-19 and antimicrobial resistance: data from the greek electronic system for the surveillance of antimicrobial resistance—WHONET-Greece (January 2018–March 2021). Life 2021 1;11. https://doi.org/10.3390/life11100996
CDC’s National Healthcare Safety Network Multidrug-Resistant Organism & Clostridioides difficile Infection (MDRO/CDI) Module [Internet]. January 2024 2024;1–52. doi: https://www.cdc.gov/nhsn/psc/cdiff/index.html
EUCAST Clinical breakpoints - breakpoints and guidance [Internet]. v 13.1 2022;15. doi: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf
H H. Analysis of Crude Data. In: Modern epidemiology, ed Rothman KJ. Boston: Little: Brown & Co; (1886)
Sahai HKA (1996) Statistics in epidemiology: methods, techniques, and applications. CRC, IncTitle;, Boca Raton, FL
MedCalc Software Ltd Confidence interval for a rate [Internet]. Version 22.018 2023 6;doi: https://www.medcalc.org/calc/rate_ci.php
Bolikas E, Astrinaki E, Panagiotaki E, Vitsaxaki E, Saplamidou S, Drositis I et al Impact of SARS-CoV-2 preventive measures against Healthcare-Associated infections from antibiotic-resistant ESKAPEE pathogens: a Two-Center, Natural Quasi-experimental Study in Greece. Antibiot 2023 22;12:1088. https://doi.org/10.3390/antibiotics12071088
Abubakar U, Al-Anazi M, alanazi Z, Rodríguez-Baño J Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: a systematic review. J Infect Public Health 2023 1;16:320–331. https://doi.org/10.1016/j.jiph.2022.12.022
Micheli G, Sangiorgi F, Catania F, Chiuchiarelli M, Frondizi F, Taddei E et al The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections. Microorganisms 2023 1;11. https://doi.org/10.3390/microorganisms11051299
Vlad ND, Cernat RC, Carp S, Mitan R, Dumitru A, Nemet C et al Predictors of carbapenem-resistant Enterobacteriaceae (CRE) strains in patients with COVID-19 in the ICU ward: a retrospective case–control study. Journal of International Medical Research 2022 1;50. https://doi.org/10.1177/03000605221129154
Liu P, Li X, Luo M, Xu X, Su K, Chen S et al Risk factors for Carbapenem-resistant Klebsiella pneumoniae infection: a Meta-analysis. Microb Drug Resist 2018 1;24:190–198. https://doi.org/10.1089/mdr.2017.0061
Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D et al Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021 1;27:520–531. https://doi.org/10.1016/j.cmi.2020.12.018
Ayoub Moubareck C, Hammoudi Halat D (2022) The collateral effects of COVID-19 pandemic on the Status of Carbapenemase-Producing pathogens. Front Cell Infect Microbiol 12:1–11. https://doi.org/10.3389/fcimb.2022.823626
doi: 10.3389/fcimb.2022.823626
Rangel K, Chagas TPG, De-Simone SG (2021) Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens 10. https://doi.org/10.3390/pathogens10081006
Zhou H, Yao Y, Zhu B, Ren D, Yang Q, Fu Y et al (2019) Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia; a retrospective study from a Chinese hospital. Med (United States) 98. https://doi.org/10.1097/MD.0000000000014937
van Dijk MD, Voor in ’t holt AF, Alp E, Hell M, Petrosillo N, Presterl E et al (2022) Infection prevention and control policies in hospitals and prevalence of highly resistant microorganisms: an international comparative study. Antimicrob Resist Infect Control. ;11:1–11. https://doi.org/10.1186/s13756-022-01165-0
Harbarth S, Cosgrove S, Carmeli Y (2002) Effects of antibiotics on nosocomial epidemiology of Vancomycin-resistant enterococci. Antimicrob Agents Chemother 46:1619–1628. https://doi.org/10.1128/AAC.46.6.1619-1628.2002
doi: 10.1128/AAC.46.6.1619-1628.2002 pubmed: 12019066 pmcid: 127216
Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R (2001) The Effect of Vancomycin and Third-Generation cephalosporins on Prevalence of Vancomycin-resistant Enterococci in 126 U.S. adult intensive care units. Ann Intern Med [Internet] 135:175–183. https://doi.org/10.7326/0003-4819-135-3-200108070-00009
doi: 10.7326/0003-4819-135-3-200108070-00009 pubmed: 11487484
Tacconelli E, De angelis G, Cataldo MA, Pozzi E, Cauda R (2008) Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61:26–38. https://doi.org/10.1093/jac/dkm416
doi: 10.1093/jac/dkm416 pubmed: 17986491
European Centre for Disease Prevention and Control (2022) Antimicrobial consumption in the EU/EEA (ESAC-Net) - Annual Epidemiological Report 2021. Stockholm
Kramer A, Wagenvoort H, Ahrén C, Daniels-Haardt I, Hartemann P, Kobayashi H et al (2010) Epidemiology of MRSA and current strategies in Europe and Japan. GMS Krankenhhyg Interdiszip [Internet] 5:Doc01. https://doi.org/10.3205/dgkh000144

Auteurs

Polyxeni Karakosta (P)

Laboratory of Clinical Microbiology, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
ORCID: 0000-0003-3768-4023

Sophia Vourli (S)

Laboratory of Clinical Microbiology, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Elisavet Kousouli (E)

Department of Clinical Microbiology, Tzaneio General Hospital of Piraeus, Athens, Greece.

Georgios Meletis (G)

Department of Microbiology, School of Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Areti Tychala (A)

Department of Microbiology, School of Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Christina Louka (C)

Department of Clinical Microbiology, Tzaneio General Hospital of Piraeus, Athens, Greece.

Alexandra Vasilakopoulou (A)

Laboratory of Clinical Microbiology, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Efthymia Protonotariou (E)

Department of Microbiology, School of Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Vasiliki Mamali (V)

Department of Clinical Microbiology, Tzaneio General Hospital of Piraeus, Athens, Greece.

Olympia Zarkotou (O)

Department of Clinical Microbiology, Tzaneio General Hospital of Piraeus, Athens, Greece.

Lemonia Skoura (L)

Department of Microbiology, School of Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Spyros Pournaras (S)

Laboratory of Clinical Microbiology, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. spournaras@med.uoa.gr.

Classifications MeSH